Gravity Analytica

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

HSDT 10.18.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-10-30

Name of Upcoming Event:The ThinkEquity Conference

Full Press Release SEC Filings Our HSDT Tweets

About Gravity Analytica

Recent Filings

NEWTOWN, Pa.,Oct. 18, 2024(GLOBE NEWSWIRE) --Helius Medical Technologies, Inc.(“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate inThe ThinkEquity ConferenceonOctober 30, 2024, at theMandarin Oriental HotelinNew York.The ThinkEquity Conferencegathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.

Management will be presenting at4:30pm ETonOctober 30^thand holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetingshere.

AboutThinkEquityThinkEquityis a boutique investment bank founded by professionals who have collaborated for over a decade, collectively financing over$50 billionin public and private capital raises, restructurings, and mergers and acquisitions. PastThinkEquityconferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect. To register to attendThe ThinkEquity Conference, please follow thislink.

AboutHelius Medical Technologies, Inc.Helius Medical Technologiesis a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS^®orHelius Medical Technologies, visitwww.heliusmedical.com.

Investor Relations ContactPhilip Trip TaylorGilmartin Groupinvestorrelations@heliusmedical.com

Source: Helius Medical Technologies, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com